eJHaem
(May 2022)
Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience
Hiromichi Takahashi,
Haruna Nishimaki,
Yoko Nakanishi,
Takashi Hamada,
Masaru Nakagawa,
Kazuhide Iizuka,
Yoshihito Uchino,
Noriyoshi Iriyama,
Katsuhiro Miura,
Tomohiro Nakayama,
Shinobu Masuda,
Yoshihiro Hatta,
Hideki Nakamura
Affiliations
Hiromichi Takahashi
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Haruna Nishimaki
Department of Pathology and Microbiology Division of Oncologic Pathology Nihon University School of Medicine Tokyo Japan
Yoko Nakanishi
Department of Pathology and Microbiology Division of Oncologic Pathology Nihon University School of Medicine Tokyo Japan
Takashi Hamada
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Masaru Nakagawa
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Kazuhide Iizuka
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Yoshihito Uchino
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Noriyoshi Iriyama
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Katsuhiro Miura
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Tomohiro Nakayama
Department of Pathology and Microbiology Division of Laboratory Medicine Nihon University School of Medicine Tokyo Japan
Shinobu Masuda
Department of Pathology and Microbiology Division of Oncologic Pathology Nihon University School of Medicine Tokyo Japan
Yoshihiro Hatta
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
Hideki Nakamura
Department of Medicine Division of Hematology and Rheumatology Nihon University School of Medicine Tokyo Japan
DOI
https://doi.org/10.1002/jha2.380
Journal volume & issue
Vol. 3,
no. 2
Abstract
Read online
Abstract Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 2018 with either standard therapy plus CNS‐directed therapy or standard therapy alone. CNS‐directed therapy was associated with a significantly better 2‐year CNS‐free survival (100% vs. 63%, p = 0.0191), despite no significant effects on progression‐free or overall survival. Further studies should assess CNS‐focused treatment in patients with IVLBCL with or without primary CNS involvement.
Keywords
WeChat QR code
Close
